mark field
Following a novel analgesic from target ID to clinical trials
Only 2% of novel analgesics will make it through clinical development. Understanding the development process for an individual pain...
top of page
.png)
THE BLOG
.png)
Expert views on Analgesic News
Search
mark field
Aug 13, 20221 min read
Complex 3D human model systems to bridge the translation gap in pain.
Key differences in pain mechanisms between preclinical species and humans have hindered the development of new analgesics. Recent...
63 views0 comments
mark field
Aug 8, 20222 min read
New study highlights need for female-focused research
A newly published article "RNA profiling of human dorsal root ganglia reveals sex-differences in mechanisms promoting neuropathic pain"...
33 views0 comments
mark field
Mar 9, 20213 min read
Vertex unlikely to repeat their CF success in Pain as they lack a personalized analgesics® approach.
Vertex are looking to other therapeutic areas to repeat their undoubted success in Cystic Fibrosis and create a sustainable pipeline....
280 views0 comments
mark field
Sep 4, 20201 min read
How to improve innovation in analgesic development: Poster presented at IASP virtual Meeting 2020.
Increasing innovation within analgesic R&D is key to identify new treatment options for millions of pain patients. I am delighted...
205 views0 comments
mark field
Aug 26, 20201 min read
Peripherally acting phase 1 pain drug acquired in $940Million deal.
Yesterday (25th Aug 2020) saw the announcement that ACADIA Pharmaceuticals acquires privately held Dallas, TX-based CerSci Therapeutics,...
332 views0 comments
mark field
Aug 18, 20202 min read
Unity Bio's novel pain drug fails in OA. Did they miss out by not using a precision approach?
"Unity Biotechnology announced the 12-week results from the Phase 2 study of UBX0101, a p53/MDM2 interaction inhibitor, in patients with...
109 views0 comments
mark field
Aug 11, 20202 min read
FDA approves Trevena’s Mu opioid for Acute pain.
Back in January 2020 the FDA had a number of expert panels voting on opioid drugs – ultimately giving negative feedback for the class. So...
261 views0 comments
mark field
Aug 7, 20202 min read
NICE guidance on chronic pain could prevent patients receiving life altering treatments
Nice guidance on chronic pain creates wrong messages and potentially stops patients receiving life altering medication. This week NICE...
177 views0 comments
mark field
Jul 7, 20202 min read
P2X3 cough drug: Negative Ph II = 70% loss of stock price but severe patient group may show the way.
Targeting the right patient population in clinical trials is key to avoiding a false negative and giving a medicine the best chance of...
120 views0 comments
mark field
May 26, 20203 min read
Biogen ready to write-off Nav1.7 assets in pain?
The last annual report for Biogen indicates worrying signs for the future development of the latest stage Nav1.7 compound Vixotrigine.
1,130 views0 comments
mark field
May 12, 20201 min read
Revolutionising pain R&D by developing Precision Analgesics
Presentation by Mark J. Field at SMI Pain Therapeutics Meeting 12th May 2020. You can find a copy of the presentation above. It covers...
141 views0 comments
mark field
Apr 20, 20204 min read
COVID19: creating a new era for 'Citizen Science'
"Citizen science" is defined as "scientific work undertaken by members of the general public, often in collaboration with or under the...
37 views0 comments
mark field
Mar 20, 20202 min read
P2X3 receptor antagonists pass Phase 3 trials for cough – potential also in pain?
P2X3 receptor channels are attractive therapeutic targets as they are expressed in sensory neurons, activated by extracellular ATP and...
249 views0 comments
mark field
Mar 17, 20202 min read
Which companies are interested in Pain? The useful analytics below LinkedIn likes & comments.
I believe LinkedIn is a great source for keeping up to date with content which can be tailored to be most relevant to you. Over the past...
163 views0 comments
mark field
Feb 21, 20203 min read
Is this still a relevant target for new pain treatments: the α2δ (Alpha2Delta) Ca2+ channel?
The traditional approach to analgesic development could be described as 'exceptionally challenging', with a clinical success rate of...
199 views0 comments
mark field
Feb 10, 20204 min read
Has a new study found a personalized approach for Nav1.7? 'Precision Analgesics' may be a better bet
The difficulties of pain research are highlighted well by the tale of the Nav1.7 sodium channel, which was thought to be the ‘holy grail’...
86 views0 comments
mark field
Feb 6, 20203 min read
So Pfizer & Lilly do ask FDA to approve Tanezumab for OA pain...
Just a few months ago some commentators had pronounced the death of Tanezumab and the whole anti-NGF class it leads, following years of...
328 views0 comments
mark field
Feb 3, 20202 min read
Vertex discontinues development of its Nav1.8 pain drug VX-961.
Deep within the Full-Year and Fourth-Quarter 2019 Financial Results for Vertex you can find this statement: “Pain: The company announced...
2,489 views0 comments
mark field
Jan 29, 20202 min read
Big data & human biomarkers – the era of citizen scientists
The probability of a new analgesic making it through clinical development is 2%. Five-times lower than other therapeutic areas. This...
39 views0 comments
bottom of page